Clinical trial
Medium Dose of Three Drugs (TPF) Concurrent Chemoradiotherapy Combined With PD-1 Checkpoint Inhibitor for Locally Advanced Esophageal Squamous Cell Carcinoma --Prospective, Single Center, Single Arm, Phase II Clinical Study (FUTURE-2)
NCT06401447 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Medium Dose of Three Drugs (TPF) Concurrent Chemoradiotherapy Combined With PD-1 Checkpoint Inhibitor for Locally Advanced Esophageal Squamous Cell Carcinoma --Prospective, Single Center, Single Arm, Phase II Clinical Study (FUTURE-2)
- Lead sponsor
- Fudan University
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- December 21, 2023
- Completion date
- July 10, 2027
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.